OMX 0407
Alternative Names: OMX-0407Latest Information Update: 04 Sep 2025
At a glance
- Originator iOmx Therapeutics
- Class Antineoplastics
- Mechanism of Action Protein tyrosine kinase inhibitors; Salt-inducible kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 May 2025 Efficacy and adverse events data from a phase I/II trial presented in Solid tumours at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 25 Apr 2025 Pharmacodynamics, pharmacokinetics and adverse events data from a phase I/II trial presented in Solid tumours at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025) .
- 25 Apr 2025 Efficacy data from a phase I trials in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)